Don’t take our word for it. Here’s every fact on this site, with its evidence grade, its caveats, and a link to the source, so you can check us.
We start you on the strong ones: findings that have been replicated or come from one large, well-controlled study. Moderate and weak facts are here too, labeled for what they are. Use “Link to this fact” to share a single card.
The industry / Animal study
Older synthetic musks (musk ambrette, AETT) caused nerve damage in animal studies and were later restricted.
Moderate evidence.
Caveats
Both primaries now read directly (2026-09-26): Spencer 1979 (AETT, N=16, single lab, single route) and Spencer 1984 (musk ambrette, N=220, dual route, dose-ranging). The musk-ambrette evidence alone is large and well-controlled enough to support 'strong', but the claim bundles it with the smaller AETT study, which keeps the combined claim at moderate under the grading rule.
Source: Pinkas 2017, Environmental Research Link to this fact
The industry / Animal study
The study's own authors, including two Research Institute for Fragrance Materials scientists, stated that the doses causing clear nerve damage in rats were 50 to 250 times their own estimate of maximum human fragrance exposure to musk ambrette, and that the lower-dose, longer-term study needed to assess real human risk was never done.
Moderate evidence: This is the study authors' own stated limitation, not an independent follow-up; no lifetime low-dose study has been conducted since (as far as this evidence base has found).
Source: Spencer 1984, Toxicology and Applied Pharmacology Industry-funded Link to this fact
The industry / Animal study
Musk ambrette is no longer used in fragrances; it was withdrawn from all skin-contact products in the 1980s, following both this neurotoxicity finding and separate reports of photoallergic skin reactions in real-world cologne use.
Moderate evidence.
Caveats
The proximate cause of the total skin-contact ban was photoallergy (Cronin 1984), not the neurotoxicity finding directly, which RIFM had already argued had an adequate safety margin via absorption data.
Source: Spencer 1984; Ford 1994, Toxicology and Applied Pharmacology Industry-funded Link to this fact
The industry / Measured in people or real products
A musk fragrance chemical called ATTN (Versalide) disappeared entirely from human tissue in this 1996 study because industry had already stopped making it in 1980, after animal testing showed it damaged nerves – a real-world example of a musk being phased out after a toxicity finding.
Moderate evidence: Absence in 19 samples is consistent with, but does not by itself prove, the discontinued-production explanation the authors give; based on a small single-country sample.
The industry / Other evidence
A fragrance fixative left on skin for hours in a lotion or perfume penetrates far more than the same chemical in a soap that is quickly rinsed off: an FDA lab's modeled estimate for musk xylol found roughly 50-60 times more absorbed mass from a 12-hour lotion application than from a 4-minute soap wash, at realistic in-use concentrations and body-surface areas.
Moderate evidence: Modeled, not directly measured for this scenario; the Kp was derived from more-permeable hairless guinea pig skin, which the authors themselves say overestimates human absorption.
Source: Hood 1996, Food and Chemical Toxicology Link to this fact
The industry / Other evidence
The flavor industry's panel says it relies on exposure, natural occurrence, structural analogy, metabolism, and animal toxicity rather than fixed test batteries, calling this the opposite of 'cookbook toxicology'; it has revoked GRAS for only 10 flavor ingredients since 1959, including musk ambrette in 1985.
Moderate evidence: Authors' own account of their program; no independent audit of the decisions is provided.
Source: Hallagan 1995, Regulatory Toxicology and Pharmacology Industry-funded Link to this fact
The industry / Other evidence
The white musk pilot's fragrance blend was developed by a Tokyo fragrance company (Nextday Co., Ltd) with Kyushu University; the company supported the study and an employee is a co-author, though the paper states no competing interests.
Moderate evidence: Funding amounts and the blend's formula are not disclosed; the authors declare no competing interests.
Source: Zennifa 2025, Scientific Reports Industry-funded Link to this fact
Information, not medical advice. See also: myths we won’t tell you.